Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT05434520 Completed - Pancreas Cancer Clinical Trials

Relieving the Bile Ducts Prior to Pancreatoduodenectomy

Start date: March 1, 2021
Phase:
Study type: Observational

The aim of this study was to assess the risk and complications after preoperative drainage of biliary obstruction in patients who underwent pancreatoduodenectomy. A retrospective cohort study of all patients who underwent pancreatoduodenectomy from January 1st, 2015 to September 30th, 2021. Patients who had preoperative bile duct drainage were compared to patients without intervention. Type of interventions, complications and outcome after surgery were compared using univariate and multivariate analysis.

NCT ID: NCT05430841 Recruiting - Pancreatic Cancer Clinical Trials

Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compared with 18F-FDG PET/CT.

NCT ID: NCT05429203 Recruiting - Clinical trials for Pancreatic Neoplasms

Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope

Start date: October 25, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to compare the success rates of procedure success and complication rates in patients undergoing Endoscopic retrograde cholangiopancreatography (ERCP) using two types of currently available endoscopes. These are (1) duodenoscope with a Single-use distal cover or (2) a conventional reusable duodenoscope.

NCT ID: NCT05428358 Recruiting - Pancreatic Cancer Clinical Trials

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

MAGIPAC
Start date: August 30, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

NCT ID: NCT05424159 Recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.

NCT ID: NCT05419479 Recruiting - Pancreatic Cancer Clinical Trials

Switch Maintenance in Pancreatic

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: - Domvanalimab (also known as AB154) - Zimberelimab (also known as AB122) - APX005M

NCT ID: NCT05417386 Recruiting - Pancreas Cancer Clinical Trials

FOLFIRINOX + NIS793 in Pancreatic Cancer

Start date: August 9, 2022
Phase: Phase 1
Study type: Interventional

This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma. The drugs involved in this study are: - NIS793 - FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin) Other interventions include - chemoradiation - surgery.

NCT ID: NCT05415917 Recruiting - Pancreatic Cancer Clinical Trials

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Start date: July 29, 2022
Phase: Phase 2
Study type: Interventional

Primary Objectives: To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone. Secondary Objectives: To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS). To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates. To assess the quality of life in patients receiving the study treatment.

NCT ID: NCT05411094 Recruiting - Clinical trials for Stage III Pancreatic Cancer AJCC v8

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Start date: May 22, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. The combination of targeted therapy with olaparib, immunotherapy with durvalumab and radiation therapy may stimulate an anti-tumor immune response and promote tumor control in locally advanced unresectable pancreatic cancer.

NCT ID: NCT05403177 Recruiting - Breast Cancer Clinical Trials

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Start date: June 23, 2022
Phase:
Study type: Observational

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients